KPMG not standing for re-appointment as Aptose auditor; material weakness disclosed

Aptose Biosciences Inc.

KPMG informed Aptose on April 15, 2025 it will not stand for re-appointment for the 2025 annual audit.
No disagreements on accounting principles or practices between KPMG and Aptose during fiscal years 2024/2023 and through April 15, 2025.
KPMG identified a material weakness in internal control over financial reporting for complex financial instruments (warrants) as per 2024 10-K.
Company has initiated process to appoint a new independent registered public accounting firm; KPMG authorized to respond to successor.
KPMG issued unqualified reports on 2024 and 2023 financial statements; no internal control report due to smaller reporting company status.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.